martes, 6 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 26, 2026

1 AI Stock I Wouldn't Touch, and 1 I Absolutely Love

View original at nasdaq.com
“In Q4, the company reported a generally accepted accounting principles (GAAP) net loss of $12.1 million.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Cloudflare's inability to turn a true profit makes its sky-high valuation too risky

    60% confidence
  • Apple is well-positioned to capture a multiyear wave of high-margin device sales while also tapping new software and services opportunities in an AI era

    60% confidence
  • New annual contract value bookings grew by nearly 50% year over year

    60% confidence
  • Apple will likely be a major AI beneficiary without having to invest the same extraordinary sums that software and cloud providers do

    60% confidence
  • Stock Advisor's total average return is 900% compared to 184% for the S&P 500

    60% confidence
  • Apple wasn't one of the 10 best stocks for investors to buy now

    60% confidence
  • Apple gives investors a front-row seat to the consumer AI revolution while providing the safety of a highly profitable, cash-generating business

    60% confidence
  • Apple's stock has a bullish outlook over the next five years

    60% confidence

Data points we hold from this source

Apple Podcasts · price to earnings ratio32 ratio
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com